Decoy Therapeutics Inc. (DCOY) Return on equity 2016–2022
Decoy Therapeutics Inc. (DCOY) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-304.4%FY2022 · since FY2016: -66.6% → -304.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -304.4% | -271.4 pp |
| FY2021 | -33.0% | +0.2 pp |
| FY2020 | -33.2% | +32.4 pp |
| FY2019 | -65.6% | — |
| FY2016 | -66.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More DCOY financial trends
DCOY RevenueDCOY Net incomeDCOY Net marginDCOY Gross profitDCOY Gross marginDCOY Operating incomeDCOY Operating marginDCOY Operating cash flowDCOY Free cash flowDCOY Capital expendituresDCOY Stock buybacksDCOY Dividends paidDCOY Total assetsDCOY Total liabilitiesDCOY Shareholders’ equityDCOY overview →